Business Wire

PCI Pharma Services Announces the Acquisition of LSNE to Add End-To-End Global Sterile Fill-Finish and Lyophilization Manufacturing Capabilities

Share

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global integrated solutions provider, announced it has signed a definitive agreement to acquire Lyophilization Services of New England, Inc. (LSNE), a premier contract development and manufacturing organization (CDMO) headquartered in Bedford, New Hampshire, from global private equity firm Permira. Founded in 1997, LSNE has an impressive history of serving global pharmaceutical, biotechnology and medical device companies, differentiated by its high-quality cGMP aseptic fill-finish capabilities, and expertise in and ability to scale lyophilization, an important manufacturing process commonly used with injectable and biologic therapies. LSNE will expand PCI’s breadth of services as a global CDMO, building on PCI’s expertise in biologics packaging and specialty manufacturing. The acquisition adds five FDA-approved facilities in the U.S. (New Hampshire, Wisconsin) and Europe (Spain), with a sixth expecting approval over the coming months, and three additional facilities under development, to strengthen PCI’s global 30-site network.

“We are excited to welcome LSNE into the PCI family,” said Salim Haffar, chief executive officer, PCI Pharma Services. “Their passion for patients, talented team, robust compliance culture, operating excellence and innovative approach to client challenges are perfectly aligned with our global strategy as PCI strives to be the bridge between life-changing therapies and patients around the world. We are particularly eager to note that this acquisition will expand our manufacturing offerings worldwide, providing clients with a single source for their drug development and packaging needs, reducing supply chain complexity and accelerating speed to market for their much-needed treatments.”

With the addition of LSNE, PCI will be able to offer integrated large and small molecule solutions for its clinical and commercial clients. This includes expanded global manufacturing capabilities in complex formulations, high potency, and now lyophilization for a broad range of injectables including nanoparticles, mRNA, mABs, proteins, oligonucleotides, and other biologics across formats from vials and bottles to pre-filled syringes and autoinjectors.

“We are delighted that LSNE is joining the PCI team and anticipate a seamless integration for our employees and clients. We have a shared focus on innovation, quality, exceptional customer service and our people,” said Matt Halvorsen, LSNE founder and CEO. “Joining forces with a global industry leader, such as PCI, is a great step forward for LSNE and will produce a winning combination for our clients, employees and the patients we jointly serve.”

LSNE marks PCI’s fourth acquisition in three years, exemplifying PCI’s enhanced focus on global specialty manufacturing capabilities while complementing its existing clinical and commercial packaging expertise. Matt Jennings, PCI Chairman, added, “On behalf of our investors we are delighted to support this strategic and transformational investment to create a top-tier global and integrated CDMO benefitting patients, clients, employees and shareholders. This milestone underscores PCI’s global strategy and commitment to be the partner of choice for specialized client needs.”

Jefferies LLC acted as exclusive financial advisor and Paul, Weiss, Rifkind, Wharton & Garrison LLP as counsel to PCI Pharma Services.

PCI is headquartered in Philadelphia, PA.

About PCI Pharma Services

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ty Guzman-Touchberry, WE Communications
tgtouchberry@we-worldwide.com / +1-212-551-4877

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bentley Education Program Expands to Global Scope25.10.2021 22:01:00 CEST | Press release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, as a commitment to expand access to its professional applications to education, today announced the global expansion of the Bentley Education program – offering seamless access to learning licenses of over 60 popular Bentley applications, at no cost, to all eligible students and educators, from middle schools through higher education levels, via the Bentley Education portal. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005717/en/ The Bentley Education program helps students develop digital skills that are critical for a qualified talent pipeline to support infrastructure growth and resilience worldwide. (Photo: Business Wire) Following on the initial May 3, 2021 announcement of the launch of Bentley Education in the pilot countries of Australia, the UK, Singapore, Lithuania, and Ireland, the program is gaining a resounding r

X-Chem Acquires ComInnex25.10.2021 20:00:00 CEST | Press release

X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery. With demand for high-quality discovery services increasing across the world, this complementary pairing of a North American leader in DEL and medicinal chemistry with a European leader in synthetic chemistry and custom DEL services delivers the capacity, footprint and expertise to better serve the demands of customers in a global market. “As a united company, with an increased global presence, we are positioned to meet the increasing demand for innovative chemistry solutions and high-quality discovery services worldwide,” noted Matt Clark, Ph.D., CEO of X-Chem. “The acquisition of ComInnex further extends X-Chem’s expertise and scale of DEL services to help bio

European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-1925.10.2021 16:30:00 CEST | Press release

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the European Commission identified lenzilumab as one of the “10 most promising treatments for COVID-19” in a report and press release issued on October 22, 2021.1,2 “We are gratified the European Commission has recognized the potential of lenzilumab to offer an important treatment option for patients hospitalized with COVID-19,” said Cameron Durrant, MD, Chairman and CEO, Humanigen. “We look forward to continuing our discussions with colleagues at the European Medicines Agency to advance our efforts to submit a marketing authorization application for lenzilumab in COVID-19. We are also progressing with our early access program, under compassionate use, where allowed by regulations in some European countries and the United States.” *Lenzilumab is not authorized, or approved

Study Finds Overwhelming Evidence That Color Blindness Hinders Learning in School, Reports EnChroma25.10.2021 14:00:00 CEST | Press release

EnChroma – creators of glasses for color blindness – today released the results of a landmark study that clearly demonstrates the negative effect color blindness has on learning for millions of students. The data strongly indicates that schools are failing to identify color blind students and that parents, educators and legislators need to better support these students. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005173/en/ Standard Color Vision and Color Blind View @EnChroma In early 2020, nearly 1,000 color blind people, including the parents of color blind children, shared their opinions about how Color Vision Deficiency (CVD) affected their educational experiences. Seventy-eight percent said they were often frustrated or confused by colors in school assignments and activities. One in three say color blindness affected their confidence in school, and 30% felt like they might be a “slow learner” before discovering

Rockefeller Capital Management to Open First International Office in London with the Formation of Rockefeller Asset Management International25.10.2021 14:00:00 CEST | Press release

Rockefeller Asset Management (RAM), a division of Rockefeller Capital Management, with a long track record of investing in global equities and ESG investing has announced the formation of Rockefeller Asset Management International, to expand its European market presence. The initial plans for expansion include opening an office in London, to better serve clients across the UK, Europe, and Asia. “Our Asset Management business has generated real momentum across Europe and we are excited to continue to serve our international clients with a full suite of sustainable investment products and a growing local presence,” said Greg Fleming, CEO and President of Rockefeller Capital Management. RAM, which was recently awarded the 2021 Principles for Responsible Investing (PRI) award for “ESG incorporation initiative of the year,” has seen strong growth in Europe. Over the last two years, the business, which surpassed $2.5 billion in assets from European investors, launched a UCITS ICAV, an Irelan

Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 202125.10.2021 14:00:00 CEST | Press release

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced the results of two key retrospective analyses at the American College of Gastroenterology 2021 annual congress. One analysis evaluated the safety and efficacy of investigational RBX2660 among a broad cohort of CDI patients with comorbidities commonly found in patients with CDI, and was recognized with a Presidential Poster Award for high-quality, novel, unique and interesting research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005099/en/ Ferring Fact Sheet While the eligibility criteria in prospective clinical trials often are narrowly defined to include patients diagnosed with only CDI, this analysis allowed researchers to evaluate the impact of RBX2660 in a patient population that is more reflective of a real-world setting. In the analysis, 94 participants with comorbid conditions commonly found in people with recurrent CDI (rCDI) were trea

CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention25.10.2021 13:53:00 CEST | Press release

Today, at a side meeting during the AU-EU Ministerial Summit in Kigali, Rwanda, Prof Salim Abdool Karim, Director of CAPRISA, announced a collaboration with a leading life science company Evotec for the designing and development of CAP256, a broadly neutralizing antibody against HIV. The project is a major expansion of the development of an antibody originally developed jointly by CAPRISA and the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases of the US NIH. This new project is a major boost for the CAP256 antibody as a potential tool in the fight against HIV in Africa and showcases the potential of African researchers to fight the continent’s high-burden diseases. The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden. CAP256, isolated from a South African woman by CAPRISA and the VRC, has demonstrated a good safety profile in Phase I studies. The next step is t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom